Comparison 10. Platinum vs non‐platinum regimens (sensitivity analysis 3: Analyses 1 repeated but with random‐effects approach).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
10.1 Overall survival	6		HR (IV, Random, 95% CI)	0.85 [0.72, 1.00]
10.2 Progression‐free survival/time to progression	8		HR (IV, Random, 95% CI)	0.62 [0.45, 0.85]
10.3 Objective tumour response rate (assessable participants)	10	1205	Risk Ratio (M‐H, Random, 95% CI)	1.49 [1.17, 1.89]